America Funds the Research. Then Penalizes You for Building on It.

Here's a story about the modern American economy in three acts:

Act One: NIH researchers at the University of California, Berkeley, funded by your taxes, discovered that the CRISPR-Cas9 gene-editing system could be adapted for use in human cells. This became the most important biotechnology of the 21st century. The research cost roughly $25 million in federal grants.

Act Two: A company called Caribou Biosciences licensed the patent. Doudna and Charpentier founded it. Eventually Emmanuelle Charpentier won the Nobel — personal award, not institutional. The CRISPR patents became worth billions. The University of California Berkeley, which funded the foundational research, had to fight a years-long legal battle to establish that it, not MIT and Harvard's Broad Institute, owned the basic IP — and it still didn't end up with the most valuable commercial rights, which went to companies that paid to license a patent the public paid to create.

Act Three: Those patents now license to drug companies that charge patients thousands of dollars per treatment for CRISPR-based therapies. The patients are you. The taxpayers funded the science. The company owns the patent. You pay again.

This is the Bayh-Dole mechanism, and it is one of the most consequential laws almost nobody has heard of.

Taxpayer funds the research. The company owns the patent. The taxpayer pays for the product. That's the deal. It's been that way since 1980.

What Bayh-Dole Actually Does

The Bayh-Dole Act of 1980 sounds boring. It sounds like the kind of thing that gets passed 97-1 with no floor debate and no press coverage. What it does is simple: it says that when a university receives federal research funding, that university can own the resulting patents instead of the federal government.

Before 1980, federal agencies — NIH, DARPA, DOE — held patents from publicly funded research. The idea was that patents funded by the public should serve the public. After Bayh-Dole, universities could exclusively license those patents to private companies. The federal government got a "non-exclusive license" — which sounds like something but isn't, in practice, worth much — and universities got to auction off exclusive rights to whatever their researchers discovered.

The argument for Bayh-Dole was that companies wouldn't invest in commercializing government-funded research unless they had exclusive rights. So you had to give them exclusivity to unlock the investment. The result: public risk, private reward. Taxpayers absorb the cost and probability of research failure; private companies capture the upside and charge the same taxpayers again for the product.

The logic is impeccable if your goal is to transfer public wealth to private shareholders. It is not an accident that pharmaceutical stock prices rose dramatically after Bayh-Dole. The act created an entire industry.

The Receipts: Every Technology You've Paid For Twice

The list of technologies that came from publicly funded research and ended up as private products is not a list of exceptions. It's basically the list of major technology advances of the last 50 years.

Technology	Public Investment	Private Outcome
The Internet (ARPANET)	DARPA / NSF funded the research, universities built the protocols	Cisco, Juniper, Akamai, cloud computing industry — trillions in value
GPS	U.S. Department of Defense, ~$12 billion in development	Garmin, TomTom, Uber, drone industry; consumer device market worth $300B+
mRNA Vaccines	NIH, DARPA funded foundational mRNA research; Kati Kariko's work was NIH-funded	Moderna (IPO: $6B, COVID vaccine $18B revenue); Pfizer/BioNTech same
CRISPR Gene Editing	NIH grants to UC Berkeley; NSF funding to Broad Institute	Licensed to Caribou, Editas, Intellia — billion-dollar biotech valuations
Fiber Optics	DOE and DARPA funded fiber optic cable development	Corning, Cisco, entire global telecommunications infrastructure
Touchscreen Technology	DARPA funded multi-touch research at MIT, others	Apple, Samsung, entire smartphone industry worth >$500B annually
Human Genome Project	NIH / DOE funded — $3.8 billion, 13-year project	Personalized medicine industry; Illumina (~$40B market cap)

The common thread: you paid for the research. A company paid a license fee (or acquired a company that held a license). The company built a product and sold it to you at market price. You paid twice. The company's shareholders pocketed the margin.

The mRNA Vaccine Specifics

The COVID pandemic made this visible in real time. Katalin Kariko's research on mRNA modification — which made the entire mRNA vaccine approach possible — was funded by NIH grants. The NIH did not patent her work directly; University of Pennsylvania did, licensed it to a company, and the resulting intellectual property became the basis for both the Moderna and Pfizer-BioNTech vaccines.

Moderna's COVID vaccine generated $18.4 billion in revenue in 2021 alone. Pfizer's generated $37 billion. NIH's contribution was foundational and publicly funded. Neither company paid the public anything close to the value it extracted. The vaccines were sold to governments at prices that reflected market power, not public investment recovery.

During the pandemic, the NIH argued it held "core" patent rights to the Moderna vaccine. Moderna countersued. The dispute is still unresolved. What is resolved: the public paid for the research, the company priced the product at whatever the market would bear, and the public paid again. The question of who legally owns the patent is separate from the question of who built the foundation — and only one of those questions got a taxpayer-funded answer.

The Counterfactual: What If Research Stayed Public?

The Bayh-Dole defense always runs as: "Without exclusive licensing, companies won't invest in development, and breakthroughs stay in the lab." This is the argument. It is not a fact.

Consider the alternative frameworks that exist, some partially implemented:

Universal Licensing: The federal government retains a non-exclusive license — meaning anyone can use the technology, but companies that commercialize it pay a reasonable royalty back to the government. The research remains in the commons; commercial development proceeds because the royalty is smaller than the value created; public recoupment flows back into the research system. The NIH has used this approach in some programs (Bayh-Dole itself allows it), but the default is exclusive licensing because universities prefer maximum control and maximum payday.

Prize Funds: Instead of giving patents to whoever can commercialize first, the government offers prizes for achieving specified outcomes. The Human Genome Project used a variant: the government funded research and published results freely, with the condition that data be made public. The result was faster genome sequencing than a patent-protected approach would have produced, with the knowledge remaining in the commons. Prize systems redirect competitive energy toward outcomes rather than IP capture — which is why incumbents hate them.

Public Option for Essential Technologies: For technologies with public health or strategic significance — mRNA platforms, broadband infrastructure — government retains ownership and licenses broadly at cost-plus, preventing the extraction dynamics. The National Institutes of Health's "fair pricing" framework (proposed in 2021, never enacted) would have required that drugs developed with significant NIH funding be priced at cost-plus-reasonable-margin.

The actual evidence on alternatives: When the federal government has retained non-exclusive licensing rights (as in some DoD technology transfers), commercial development has still proceeded. The lack of exclusivity doesn't prevent commercial investment — it prevents commercial monopoly. Companies invest to build better products, not just to hold a patent. The monopoly premium is the thing being optimized for, not the thing that unlocks investment.

The technology licensing literature is consistent: The primary driver of commercial R&D investment is expected market size, not IP protection from government research. Companies invest because customers want the product, not because a university assigned them an exclusive patent.

The Cross-Partisan Problem

Here's where this connects beyond the economics: this is one of the few issues where both the left and the right have genuine grievances — and both are usually played for fools.

From the left: Public money should serve the public. When the NIH funds research that produces a billion-dollar drug, the public should not pay twice — once for the research, again for the drug. The pharmaceutical industry lobbying against Medicare negotiation and against NIH pricing frameworks is the same industry that extracts maximum rent from publicly funded science. The policy position is simple: if the public funds it, the public should own a share of the upside or at minimum not pay again.

From the right: The federal government should not be picking winners through patent assignment. When NIH-funded research goes to a politically connected biotech company that then charges whatever it wants, the free market isn't working — a privileged class is capturing government-granted monopoly power. The irony of Bayh-Dole defenders arguing "but this incentivizes private investment" in the same breath they oppose price controls is not lost: they're using the language of free markets to defend a system where government directly transfers monopoly rights to preferred companies.

The corruption link: Universities have enormous financial incentives to maximize licensing revenue. The technology transfer industry — the offices at MIT, Stanford, UC Berkeley that handle licensing — generates hundreds of millions per year in licensing fees. The people running those offices have strong incentives to push exclusive licenses over non-exclusive ones. The result is a structural bias toward maximum extraction rather than maximum public benefit — embedded in the incentives of the institutions we trust to manage public research funds.

The revolving door between NIH, the FDA, and the pharmaceutical industry is a related problem. The same people who oversaw NIH funding decisions end up at pharmaceutical companies that license the resulting patents. The regulatory capture we wrote about in the context of lobbying operates here too: the agency's former employees benefit from decisions that favor the industry they now represent.

What the System Actually Produces

The evidence on whether Bayh-Dole achieved its stated goal — accelerating commercial application of publicly funded research — is mixed at best.

Studies by the Association of American Universities and independent economists find that the fraction of federally funded research that leads to commercialized products is small. Most university patents are never licensed. Most licensing revenue comes from a tiny fraction of patents. The overall technology transfer system — offices, staff, legal costs, licensing negotiations — consumes a substantial fraction of the value it generates.

The more important question is what the system forecloses. When a company holds exclusive rights to a publicly funded discovery, alternatives don't get developed. Prices stay high because there's no competition. Research directions get locked in because the patent holder has no incentive to pursue alternatives. The dynamic that Bayh-Dole was supposed to unlock — faster development, more applications — is often the opposite of what happens when a single company controls the IP.

Compare the mRNA vaccine story to the Human Genome Project: the HGP published data publicly and let anyone use it. The result was faster sequencing, more research applications, and a broader commercial ecosystem than a single-company licensing model would have produced. That's the counterfactual. That's what non-exclusive, publicly-directed research looks like when you let it.

The Fix Isn't Complicated

None of this requires dismantling the research system. The fix is to change the terms of the transfer:

Non-exclusive licensing as the default. Federal funding agreements should default to non-exclusive licensing unless the agency head specifically approves exclusive licensing for a defined application. Royalty revenues flow back to the funding agency, which re-invests in research. This is allowed under current law — it's just not the default.

Government use rights with pricing constraints. When a technology developed with significant federal funding reaches commercialization, the government retains the right to license at cost in defined circumstances (public health emergencies, strategic infrastructure). This is essentially what the march-in rights provision in Bayh-Dole was supposed to provide — but it has never been successfully invoked.

Prize mechanisms for high-value targets. For technologies where the commercial application is clear but the research is risky, government should offer prizes for achieving defined outcomes. The prize replaces the patent as the incentive — companies compete to be first, but the knowledge becomes public once the prize is claimed.

Technology transfer reform: The licensing offices at major research universities are profit centers. That profit motive pushes toward maximum extraction over maximum public benefit. Changing their incentive structure — requiring non-exclusive as default, capping royalty rates on essential applications — would realign their interests with the public they nominally serve.

None of this requires choosing between innovation and public benefit. It requires refusing to accept a system where public funding creates private monopolies that charge the same public again for the product.

The deal was supposed to be: we fund research, you develop it, everyone benefits. What we got was: we fund research, you own it, we pay again. That gap — between the promise and the performance — is the policy error worth closing.

The Other Half: Starting the Company

Bayh-Dole is the problem upstream. But even if you fix that — even if you get the patent rights back into the commons — you still have to start the company. And America's startup infrastructure actively discourages it.

Healthcare. The number one reason founders give for not starting a company: their family's health insurance. When coverage is tied to employment, leaving your job means losing coverage for your spouse and kids. That risk is asymmetric — a well-funded incumbent can offer benefits as part of the compensation package; a first-time founder cannot. The policy solution is obvious: decoupling healthcare from employment, which we've written about in depth. The result would be immediate: more founders, more competition, more risk-taking in the economy.

Business formation. In New Zealand, you can incorporate a company in under an hour, online, for $50. In the US, the time to open a business bank account varies from three days to three months depending on your state and the bank. The average cost of regulatory compliance for a new small business is $10,000 in the first year. That's a tax on trying. One-day, one-form federal business formation — the same way you get a Social Security number — would eliminate that friction entirely.

Bankruptcy law. The US has some of the harshest bankruptcy consequences for entrepreneurs of any developed country. Student debt can't be discharged in bankruptcy. Business debt carries long-term consequences for personal credit. The result: the most talented potential founders — the ones who might fail once before getting it right — are either priced out of starting or permanently disqualified when they try and fail. A system that punishes good-faith failure doesn't encourage risk. It selects for the already-wealthy.

R&D tax credits. The US R&D credit exists. But it's largely inaccessible to early-stage companies — the compliance cost to claim it exceeds the benefit for most companies under $5M in revenue. Large corporations with dedicated tax departments capture 90% of the credit's value. Making R&D credits available to companies under $10M in revenue as an automatic offset — no complicated application, just a line item on the tax return — would redirect the policy toward the companies actually building things.

The common thread across all four: the current system optimizes for incumbents. Healthcare ties workers to large employers. Regulatory overhead favors companies that can afford compliance departments. Bankruptcy law punishes founders who aren't wealthy enough to absorb failure. R&D credits go to companies that can afford to hire tax counsel to claim them. None of this is accidental. The people who designed these systems were already inside them.

The Uncomfortable Reality

Here's what the full picture looks like: America funds basic research through NIH, DARPA, and the NSF. That research produces breakthroughs. Bayh-Dole transfers the resulting patents to private companies, which extract maximum rent from the public that funded the research in the first place. And then, for the rare entrepreneur who wants to build a new company on top of those breakthroughs — or anywhere else — the system layers on healthcare costs, regulatory friction, bankruptcy risk, and R&D credits that don't apply to them.

This is not a failure of any one policy. It's the cumulative effect of a system designed around the interests of the people already inside it. The same people who fund the research also lobby for the patent transfer. The same large companies that benefit from Bayh-Dole also benefit from healthcare tied to employment. The same tax attorneys who draft the R&D credit also draft the compliance requirements that make it unusable for anyone but them.

Fixing this isn't about choosing between public research and private entrepreneurship. It's about understanding that the two are supposed to work together — and redesigning the handoff so they actually do.

Public research feeds private commercialization. Private commercialization funds public investment. That's the cycle. Right now it's broken in both directions: public pays for research, gets charged for the product. And then gets penalized again for trying to build the next thing.